In clinical trials, bepirovirsen showed the potential to address a significant unmet medical need for patients with chronic hepatitis B by reducing hepatitis B surface antigen levels and HBV DNA.
FDA Fast Tracks GSK's Bepirovirsen for Chronic Hepatitis B Virus
Posted on by admin
![](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
1 min read
+ There are no comments
Add yours